Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00798603 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving pemetrexed together with carboplatin and bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving pemetrexed together with carboplatin and bevacizumab works as first-line therapy in treating older patients with stage IIIB or stage IV non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- BIOLOGICAL bevacizumab
- DRUG pemetrexed disodium
Study Locations (20)
Colorado
- Aurora Presbyterian Hospital — Aurora
- Boulder Community Hospital — Boulder
- Penrose Cancer Center at Penrose Hospital — Colorado Springs
- St. Anthony Central Hospital — Denver
- Porter Adventist Hospital — Denver
- Presbyterian - St. Luke's Medical Center — Denver
- St. Joseph Hospital — Denver
- Rose Medical Center — Denver
- CCOP - Colorado Cancer Research Program — Denver
- Swedish Medical Center — Englewood
- Front Range Cancer Specialists — Fort Collins
- St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center — Grand Junction
- North Colorado Medical Center — Greeley
- Sky Ridge Medical Center — Lone Tree
- Hope Cancer Care Center at Longmont United Hospital — Longmont
- McKee Medical Center — Loveland
- St. Mary - Corwin Regional Medical Center — Pueblo
- North Suburban Medical Center — Thornton
- Exempla Lutheran Medical Center — Wheat Ridge
Arizona
- Mayo Clinic Scottsdale — Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00798603
The ClinicalTrials.gov registry entry for NCT00798603 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions — of which carboplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00798603 reports 20 study locations spanning 2 distinct geographic areas — top geographies include Colorado, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00798603 about?
NCT00798603 is a clinical study titled "Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibo...
What is the current status of trial NCT00798603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2008-12. Estimated completion is 2013-05.
What conditions does trial NCT00798603 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00798603?
The interventions under investigation include: carboplatin (DRUG), bevacizumab (BIOLOGICAL), pemetrexed disodium (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00798603?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00798603 being conducted?
This trial has 20 study locations across Arizona, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.